$2.60
-0.10 (-3.70%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GNLX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 expanded access · 1 with posted results
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, Point72 Asset Management, L.P., Hudson Bay Capital Management LP) · FINRA short interest 20.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: Olvimulogene nanivacirepvec · Drug: Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel | Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | 142 | Feb 2027 | ≤ 193 d | 2026-06-04 |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: olvimulogene nanivacirepvec · Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 186 | Dec 2026 | ≤ 134 d | 2026-07-10 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerNCT02759588results2026-06-12Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Olvi-Vec · Drug: Platinum-doublet with or without bevacizumab | Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer | 46 | 2021-12-31actual | — | 2026-06-12 |
| Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck CancerNCT01584284Safety and Tolerability as measured by the number of patients with Adverse Events, as well as type of AE and frequencyOpen-label · Treatment | Phase 1 | Completed | Biological: GL-ONC1 | Cancer of Head and Neck | 19 | Jun 2015actual | — | 2015-08-25 |
| Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of CareNCT03420430expanded access | — | No longer available | Biological: GL-ONC1 | Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients) | — | — | — | 2024-09-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19